跳至主要内容
临床试验/NCT04418180
NCT04418180已完成不适用

Fenofibrate as an Adjuvant to Phototherapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants: A Randomized Control Trial.

Mansoura University0 个研究点开始时间: 2016年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
主要终点
Total serum bilirubin

研究概览

简要总结

Background: Despite widespread phototherapy usage, many newborn infants remain in need of other lines of invasive therapy such as intravenous immunoglobulins and exchange transfusions.

Objective: To assess the efficacy and the safety of adding fenofibrate to phototherapy for treatment of pathological jaundice in full term infants.

Design/Methods: We conducted a double blinded randomized control study on 180 full-term infants with pathological unconjugated hyperbilirubinemia admitted to the NICU of Mansoura University Children's Hospital. They were randomly assigned to receive either oral fenofibrate 10 mg /kg /day for one day or two days or placebo. Primary outcome was total serum bilirubin values after 12, 24, 36, 48 hours from intervention. Secondary outcomes were total duration of treatment, need for exchange transfusions and intravenous immunoglobulin, exclusive breast-feeding on discharge, and adverse effects of fenofibrate.

研究设计

研究类型
Interventional

入排标准

年龄范围
— 至 28 Days(Child)
性别
All
接受健康志愿者

入选标准

  • we included appropriate for gestational age full-term infants with pathological unconjugated hyperbilirubinemia who are candidate for phototherapy according to American academy of pediatrics guidelines

排除标准

  • Full term infants with intrauterine growth restriction, congenital malformations, conjugated hyperbilirubinemia, severe jaundice initially required exchange transfusion, skin abrasions or infection, and preterm infants were excluded

研究组 & 干预措施

GROUP3

Placebo Comparator

photo therapy only

干预措施: Placebo (Drug)

GROUP1

Active Comparator

group receiving single dose fenofibrate

干预措施: Fenofibrate (Drug)

GROUP2

Active Comparator

group receiving double dose fenofibrate

干预措施: Fenofibrate (Drug)

结局指标

主要结局

Total serum bilirubin

时间窗: 72 hours of treatment

measure level of serum total bilirubin (mg/dl)

次要结局

  • length of hospital stay(expected 3 days of treatment)
  • duration of photo therapy(expected 48 hours of treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Abd Elazeez Attala Shabaan

Professor

Mansoura University

相似试验